Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Nicola Huxley"'
Autor:
Helen Coelho, Tracey Jones-Hughes, Tristan Snowsill, Simon Briscoe, Nicola Huxley, Ian M. Frayling, Chris Hyde
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-13 (2017)
Abstract Background A systematic review was conducted to assess the diagnostic test accuracy of polymerase chain reaction (PCR)-based microsatellite instability (MSI) testing for identifying Lynch syndrome in patients with colorectal cancer (CRC). Un
Externí odkaz:
https://doaj.org/article/60e8cb7d51c043d593d3f371eb4908f2
Autor:
Tristan Snowsill, Helen Coelho, Nicola Huxley, Tracey Jones-Hughes, Simon Briscoe, Ian M Frayling, Chris Hyde
Publikováno v:
Health Technology Assessment, Vol 21, Iss 51 (2017)
Background: Inherited mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR) genes lead to an increased risk of colorectal cancer (CRC), gynaecological cancers and other cancers, known as Lynch syndrome (LS). Risk-reducing interventions can b
Externí odkaz:
https://doaj.org/article/a28119057068442088c4768b10896aba
Autor:
Nicola Huxley, Louise Crathorne, Jo Varley-Campbell, Irina Tikhonova, Tristan Snowsill, Simon Briscoe, Jaime Peters, Mary Bond, Mark Napier, Martin Hoyle
Publikováno v:
Health Technology Assessment, Vol 21, Iss 38 (2017)
Background: Colorectal cancer is the fourth most commonly diagnosed cancer in the UK after breast, lung and prostate cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line
Externí odkaz:
https://doaj.org/article/b41c56cbf6b34b4f8fbc5d9914b1688d
Autor:
Tracey Jones-Hughes, Tristan Snowsill, Marcela Haasova, Helen Coelho, Louise Crathorne, Chris Cooper, Ruben Mujica-Mota, Jaime Peters, Jo Varley-Campbell, Nicola Huxley, Jason Moore, Matt Allwood, Jenny Lowe, Chris Hyde, Martin Hoyle, Mary Bond, Rob Anderson
Publikováno v:
Health Technology Assessment, Vol 20, Iss 62 (2016)
Background: End-stage renal disease is a long-term irreversible decline in kidney function requiring renal replacement therapy: kidney transplantation, haemodialysis or peritoneal dialysis. The preferred option is kidney transplantation, followed by
Externí odkaz:
https://doaj.org/article/6306c66859f44bfebcf6fdd65b381a00
Autor:
Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Louise Crathorne, Chris Cooper, Jo Varley-Campbell, Ruben Mujica-Mota, Helen Coelho, Nicola Huxley, Jenny Lowe, Jan Dudley, Stephen Marks, Chris Hyde, Mary Bond, Rob Anderson
Publikováno v:
Health Technology Assessment, Vol 20, Iss 61 (2016)
Background: End-stage renal disease is a long-term irreversible decline in kidney function requiring kidney transplantation, haemodialysis or peritoneal dialysis. The preferred option is kidney transplantation followed by induction and maintenance im
Externí odkaz:
https://doaj.org/article/6b5548ce11a64adaacbec4c27a8f12f8
Autor:
Louise Crathorne, Nicola Huxley, Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Martin Hoyle, Simon Briscoe, Helen Coelho, Linda Long, Antonieta Medina-Lara, Ruben Mujica-Mota, Mark Napier, Chris Hyde
Publikováno v:
Health Technology Assessment, Vol 20, Iss 13 (2016)
Background: Anaemia is a common side effect of cancer treatments and can lead to a reduction in quality of life. Erythropoiesis-stimulating agents (ESAs) are licensed for use in conjunction with red blood cell transfusions to improve cancer treatment
Externí odkaz:
https://doaj.org/article/ac072a1baabe43b897806d575f509e6a
Autor:
Nicola Huxley, Tracey Jones-Hughes, Helen Coelho, Tristan Snowsill, Chris Cooper, Yang Meng, Chris Hyde, Rubén Mújica-Mota
Publikováno v:
Health Technology Assessment, Vol 19, Iss 2 (2015)
Background: In breast cancer patients, sentinel lymph node biopsy is carried out at the same time as the removal of the primary tumour to postoperatively test with histopathology for regional metastases in the sentinel lymph node. Those patients with
Externí odkaz:
https://doaj.org/article/15550f205c1a4d588293cb6817361d31
Autor:
Tristan Snowsill, Nicola Huxley, Martin Hoyle, Tracey Jones-Hughes, Helen Coelho, Chris Cooper, Ian Frayling, Chris Hyde
Publikováno v:
Health Technology Assessment, Vol 18, Iss 58 (2014)
Background: Lynch syndrome (LS) is an inherited autosomal dominant disorder characterised by an increased risk of colorectal cancer (CRC) and other cancers, and caused by mutations in the deoxyribonucleic acid (DNA) mismatch repair genes. Objective:
Externí odkaz:
https://doaj.org/article/858d18a9c304498f84ed573006b2f1fb
Autor:
James Killen, Suzanne Hughes, Michael Caruana, Robyn L. Ward, Gillian Mitchell, Alex Boussioutas, Tristan Snowsill, Veerle M.H. Coupé, Finlay A. Macrae, Yoon-Jung Kang, Ian M. Frayling, Kate T. Simms, Natalie Taylor, Nicola Huxley, Alison H. Trainer, Victoria Freeman, Karen Canfell
Publikováno v:
Kang, Y-J, Killen, J, Caruana, M, Simms, K, Taylor, N, Frayling, I M, Snowsill, T, Huxley, N, Coupe, V M H, Hughes, S, Freeman, V, Boussioutas, A, Trainer, A H, Ward, R L, Mitchell, G, Macrae, F A & Canfell, K 2020, ' The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome ', Medical Journal of Australia, vol. 212, no. 2, pp. 72-81 . https://doi.org/10.5694/mja2.50356
Medical Journal of Australia, 212(2), 72-81. Australasian Medical Publishing Co. Ltd
Medical Journal of Australia, 212(2), 72-81. Australasian Medical Publishing Co. Ltd
OBJECTIVES:\ud \ud To evaluate the health impact and cost-effectiveness of systematic testing for Lynch syndrome (LS) in people with incident colorectal cancer (CRC) in Australia.\ud DESIGN, SETTING, PARTICIPANTS:\ud \ud We investigated the impact of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b09c236383590a1f4820cc635503e3d
Autor:
Nicola Huxley, Louise Crathorne, Mark Napier, Irina A Tikhonova, Martin Hoyle, Tristan Snowsill, Jo Varley-Campbell
Publikováno v:
PharmacoEconomics. 36:837-851
Combination therapies with cetuximab (Erbitux®; Merck Serono UK Ltd) and panitumumab (Vectibix®; Amgen UK Ltd) are shown to be less effective in adults with metastatic colorectal cancer who have mutations in exons 2, 3 and 4 of KRAS and NRAS oncoge